Optimizing the Pharmacological Profile of New Bifunctional Antihyperlipidemic/Antioxidant Morpholine Derivatives.
Journal
ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073
Informations de publication
Date de publication:
10 Jan 2019
10 Jan 2019
Historique:
received:
08
10
2018
accepted:
18
12
2018
entrez:
19
1
2019
pubmed:
19
1
2019
medline:
19
1
2019
Statut:
epublish
Résumé
Among the causal risk factors directly promoting the development of coronary and peripheral atherosclerosis are reactive oxygen species and elevated low-density lipoprotein plasma levels. We hereby designed new potent squalene synthase (SQS) inhibitors that may simultaneously tackle the oxidative stress induced by lipid peroxidation. Using previously developed morpholine derivatives as a starting point, we conducted extensive structural changes by either substituting or modifying the morpholine ring, aiming at an optimal SQS-antioxidant pharmacological profile. Compounds
Identifiants
pubmed: 30655954
doi: 10.1021/acsmedchemlett.8b00469
pmc: PMC6331192
doi:
Types de publication
Journal Article
Langues
eng
Pagination
98-104Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Pharm Res. 1999 Jul;16(7):1093-7
pubmed: 10450936
Biochemistry. 1999 Oct 5;38(40):13138-46
pubmed: 10529185
J Med Chem. 2000 Feb 24;43(4):609-12
pubmed: 10691687
Acta Physiol Hung. 1999;86(1):57-68
pubmed: 10755170
Inorg Chem. 2000 Aug 21;39(17):3875-80
pubmed: 11196783
Curr Opin Lipidol. 2002 Aug;13(4):415-20
pubmed: 12151857
J Med Chem. 2002 Sep 26;45(20):4571-80
pubmed: 12238936
J Med Chem. 2002 Nov 21;45(24):5406-9
pubmed: 12431068
Nature. 2002 Dec 19-26;420(6917):868-74
pubmed: 12490960
Biochem Pharmacol. 2003 Dec 1;66(11):2133-9
pubmed: 14609738
J Lipid Res. 1992 Nov;33(11):1657-63
pubmed: 1464749
Atherosclerosis. 2005 Aug;181(2):215-24
pubmed: 15893757
Curr Pharm Des. 2005;11(16):2017-32
pubmed: 15974956
Ann N Y Acad Sci. 1992 Apr 15;650:19-24
pubmed: 1605475
Curr Atheroscler Rep. 2007 Jan;9(1):78-80
pubmed: 17169251
J Med Chem. 2008 Sep 25;51(18):5861-5
pubmed: 18754614
Lancet. 2010 Feb 27;375(9716):735-42
pubmed: 20167359
Bioorg Med Chem. 2010 Nov 1;18(21):7402-12
pubmed: 20888243
J Med Chem. 2011 Aug 11;54(15):5583-91
pubmed: 21702499
Curr Med Chem. 2011;18(29):4418-39
pubmed: 21864285
Eur J Intern Med. 2012 Jun;23(4):317-24
pubmed: 22560377
J Med Chem. 2013 Apr 25;56(8):3330-8
pubmed: 23581491
J Med Chem. 2014 Mar 27;57(6):2568-81
pubmed: 24568631
J Pharmacol Pharmacother. 2014 Jul;5(3):181-5
pubmed: 25210397
Bioorg Med Chem. 2015 Nov 1;23(21):7015-23
pubmed: 26433631
Pharmacol Ther. 2017 Jul;175:1-16
pubmed: 28223230
J Med Chem. 2018 Apr 26;61(8):3609-3625
pubmed: 29634260
J Med Chem. 1978 May;21(5):460-4
pubmed: 660590
Prog Cardiovasc Dis. 1995 Sep-Oct;38(2):129-54
pubmed: 7568903
Circulation. 1995 May 1;91(9):2488-96
pubmed: 7729036
Toxicol Appl Pharmacol. 1995 Mar;131(1):163-74
pubmed: 7878672
J Med Chem. 1993 May 14;36(10):1465-73
pubmed: 8496914
Biochim Biophys Acta. 1977 Oct 24;489(1):119-25
pubmed: 911870
Biochem J. 1976 Jun 15;156(3):539-43
pubmed: 949335